SEDLine acquires Hospira's BFM business

SEDLine™, Inc., announced today that it has acquired the brain function monitoring business of Hospira, Inc. (NYSE:HSP). Privately held and backed with an investment from Masimo Corporation (NASDAQ:MASI), SEDLine, Inc., based in Irvine, California, was formed with the mission to advance neuromonitoring technologies to improve the care of patients under anesthesia or sedation.

“Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications.”

Brain function monitoring (BFM) has become a widely utilized modality for assessing depth of anesthesia and sedation. Based primarily on analysis of the electroencephalogram (EEG), brain function monitors continuously measure the electrical activity of the brain and translate those changes to the level of consciousness. BFM has been deployed in a variety of clinical environments, ranging from the operating room for patients having surgery, to intensive care units where critically ill patients can be sedated for prolonged periods, and in short procedure units where patients undergo procedures such as colonoscopy and endoscopy.

SEDLine’s technology is based on 10 years of innovation and offers a cost-effective alternative to other monitors, while delivering proven 4-channel EEG integrated algorithm performance, demonstrated reliability under challenging clinical conditions and superior resistance to cautery.

David E. Goodman, MD, MSE, President & CEO, SEDLine commented, “We are very excited to acquire the SEDLine brain function monitoring platform from Hospira. We intend to continue Hospira’s tradition of providing outstanding support for its customers. To reinforce our commitment to the newly acquired product line, the original Hospira Brain Function Monitoring team has joined SEDLine, Inc., ensuring that we will be able to provide all of the products, service, and support previously received from Hospira.”

Joe E. Kiani, Founder, Chairman and CEO of Masimo Corporation, commented, “We are happy to be able to provide an investment in SEDLine to help it advance and improve brain function monitoring for patients under anesthesia and sedation. Their clear commitment to invest in R&D as well as to offer excellent customer care resonates well with Masimo, and we wish them great success as they launch their new company.”